A personalized mRNA therapy teamed with the immunotherapy KEYTRUDA has produced striking five-year results in patients with high-risk melanoma, cutting the chance of recurrence or death by roughly half in a randomized trial. The therapy, intismeran autogene, is made from each patient’s tumor mutations and was tested against pembrolizumab alone in a phase 2b clinical trial presented at ASCO. Results show durable benefit, an acceptable safety profile, and ongoing late-stage testing to confirm those gains.
The study was a collaboration between Merck and Moderna and was shared at the American Society of Clinical Oncology meeting in Chicago on May 27. Researchers followed patients for about five years to see how many would have their cancer return or succumb after standard surgery. That long view is what makes this readout notable compared with many shorter trials.
In the KEYNOTE-942 phase 2b trial, the combination of intismeran autogene plus KEYTRUDA reduced the risk of melanoma recurrence or death by 49 percent compared with pembrolizumab alone. That relative risk reduction held up over the extended follow-up window, which matters for patients facing long-term relapse risk. It’s a clear signal that pairing personalized mRNA with checkpoint blockade can change the trajectory after surgical tumor removal.
The trial enrolled 157 patients with high-risk stage 3 and 4 melanoma who had their tumors surgically removed, then randomized them into two arms. One arm received the combo of the personalized vaccine and pembrolizumab, while the control arm received pembrolizumab on its own. That design isolates whether the tailored mRNA component adds protection beyond what KEYTRUDA already provides.
Intismeran autogene is built from mutations discovered in a patient’s own tumor, so the vaccine teaches the immune system to recognize the cancer’s unique fingerprints. The idea is straightforward and elegant: point immune cells at precisely the abnormal proteins the tumor carries, then let checkpoint inhibition sustain the attack. This personalized approach contrasts with one-size-fits-all cancer vaccines and aims to sharpen immune targeting.
Investigators described the combo’s benefits as “sustained and durable over time.” Durability matters because early responses that fade leave patients exposed to later recurrence, while a lasting immune memory can keep cancer at bay. Seeing that kind of persistence at roughly five years gives clinicians more confidence in the regimen’s potential long-term value.
Safety was manageable and acceptable in the trial, and the therapy was reported to be “well-tolerated” with a “manageable” safety profile. The most common side effects were fatigue, injection-site pain, chills, fever and headache, and researchers found no new long-term safety concerns or severe vaccine-related adverse events. Those tolerability findings matter, since adding a personalized vaccine shouldn’t trade effectiveness for unacceptable toxicity.
The combination is now being evaluated in a larger phase 3 study as the final confirmation step before broader approval would be considered. The companies also pointed to additional late-stage INTerpath trials with Moderna that are exploring the platform in several hard-to-treat cancers. Those programs will test whether this personalized mRNA work scales beyond melanoma into other indications where immune precision could help.
Kyle Holen, MD, Moderna’s senior vice president and head of development, oncology and therapeutics, noted that this data highlights the “potential of a prolonged benefit … in patients with resected high-risk melanoma.” He added, “We continue to invest in our platform in oncology because of encouraging outcomes like these, which illustrate mRNA’s potential in cancer care.” Those comments frame the results as both clinically meaningful and strategically important for mRNA oncology development.
Dr. Marjorie Green, senior vice president and head of oncology, global clinical development at Merck Research Laboratories, emphasized the clinical need, pointing out that for many patients with stage 3 or 4 disease there is a “significant risk of recurrence following surgery.” “As such, demonstrating the longer-term potential of intismeran autogene and KEYTRUDA to reduce the risk of recurrence for certain patients with melanoma is a meaningful milestone,” she said. The companies noted the encouraging five-year follow-up and signaled more data are coming from late-stage trials.
